CN119325480A - 靶向cxcr4的化合物及其制备和使用方法 - Google Patents

靶向cxcr4的化合物及其制备和使用方法 Download PDF

Info

Publication number
CN119325480A
CN119325480A CN202380039010.3A CN202380039010A CN119325480A CN 119325480 A CN119325480 A CN 119325480A CN 202380039010 A CN202380039010 A CN 202380039010A CN 119325480 A CN119325480 A CN 119325480A
Authority
CN
China
Prior art keywords
residue
compound
lys
independently
ipr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202380039010.3A
Other languages
English (en)
Chinese (zh)
Inventor
弗朗索瓦·贝纳德
国-贤·林
利·利·李
正兴·张
丹尼尔·权
大卫·佩林
米哈伊洛·托多罗维奇
约瑟夫·刘
山姆森·莱
秀-婷·郭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alpha 9 Oncology Co
University of British Columbia
Provincial Health Services Authority
Original Assignee
Alpha 9 Oncology Co
University of British Columbia
Provincial Health Services Authority
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alpha 9 Oncology Co, University of British Columbia, Provincial Health Services Authority filed Critical Alpha 9 Oncology Co
Publication of CN119325480A publication Critical patent/CN119325480A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/13—Labelling of peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CN202380039010.3A 2022-04-20 2023-04-20 靶向cxcr4的化合物及其制备和使用方法 Pending CN119325480A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202263332885P 2022-04-20 2022-04-20
US63/332,885 2022-04-20
PCT/CA2023/050538 WO2023201435A1 (en) 2022-04-20 2023-04-20 Cxcr4-targeting compounds, and methods of making and using the same

Publications (1)

Publication Number Publication Date
CN119325480A true CN119325480A (zh) 2025-01-17

Family

ID=88418769

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202380039010.3A Pending CN119325480A (zh) 2022-04-20 2023-04-20 靶向cxcr4的化合物及其制备和使用方法

Country Status (7)

Country Link
US (1) US20250242064A1 (https=)
EP (1) EP4511384A1 (https=)
JP (1) JP2025513489A (https=)
CN (1) CN119325480A (https=)
AU (1) AU2023257191A1 (https=)
CA (1) CA3249424A1 (https=)
WO (1) WO2023201435A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120137854A (zh) * 2025-05-13 2025-06-13 中国农业大学 一种具有广泛pH适应性的有机磷矿化复合菌群及其应用

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025218761A1 (zh) * 2024-04-17 2025-10-23 晶核生物医药科技(上海)有限公司 环状肽类化合物、其药物组合物及其应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2377579A1 (en) * 2007-05-30 2011-10-19 Eli Lilly and Company Cyclic peptide CXCR4 antagonists
KR20230145543A (ko) * 2017-09-05 2023-10-17 메인라인 바이오사이언스 고친화성 cxcr4 선택적 결합 콘쥬게이트 및 그 사용 방법
JP2021165234A (ja) * 2018-07-03 2021-10-14 富士フイルム富山化学株式会社 Ｃｘｃｒ４結合性化合物もしくはその塩またはそれらと金属との錯体
US20220218852A1 (en) * 2019-04-18 2022-07-14 Provincial Health Services Authority Novel radiolabelled cxcr4-targeting compounds for diagnosis and therapy
JP2023549469A (ja) * 2020-10-21 2023-11-27 プロビンシャル・ヘルス・サービシーズ・オーソリティ 新規ｃｘｃｒ４標的化合物

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN120137854A (zh) * 2025-05-13 2025-06-13 中国农业大学 一种具有广泛pH适应性的有机磷矿化复合菌群及其应用
CN120137854B (zh) * 2025-05-13 2025-09-23 中国农业大学 一种具有广泛pH适应性的有机磷矿化复合菌群及其应用

Also Published As

Publication number Publication date
JP2025513489A (ja) 2025-04-24
EP4511384A1 (en) 2025-02-26
WO2023201435A1 (en) 2023-10-26
CA3249424A1 (en) 2023-10-26
WO2023201435A8 (en) 2023-12-28
US20250242064A1 (en) 2025-07-31
AU2023257191A1 (en) 2024-10-10

Similar Documents

Publication Publication Date Title
CN114401947B (zh) 靶向前列腺特异性膜抗原的放射性标记化合物
US20240350681A1 (en) Radiolabeled melanocortin 1 receptor-specific alpha-melanocyte-stimulating hormone analogues for imaging or therapy
JP7541532B2 (ja) 診断及び治療のための新規な放射性標識されたｃｘｃｒ４を標的とする化合物
AU2021366975A1 (en) Novel CXCR4-targeting compounds
AU2020257786A1 (en) Novel radiolabelled compounds for diagnosis or treatment of prostate-specific membrane antigen-expressing cancer
JP2025507971A (ja) 前立腺特異的膜抗原を標的とする放射性標識化合物
WO2023133645A1 (en) Radiolabeled compounds for imaging of fibroblast activation protein (fap) and treatment of fap-related disorders
CN119325480A (zh) 靶向cxcr4的化合物及其制备和使用方法
WO2024016071A1 (en) Radiolabeled compounds targeting the prostate-specific membrane antigen
US20250195702A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
US12616761B2 (en) CXCR4-targeting compounds
WO2025054727A1 (en) Radiolabeled compounds for in vivo imaging of gastrin-releasing peptide receptor (grpr) and treatment of grpr-related disorders
WO2025111712A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof
WO2026055788A1 (en) Gastrin-releasing peptide receptor (grpr)-targeted compounds and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination